Coagulation factor X (activated) (FXa)

Rivaroxaban is not itself a molecular target or receptor; it is a **small-molecule anticoagulant drug** that acts as a **direct inhibitor of activated coagulation factor X (Factor Xa)**. The actual therapeutic target for rivaroxaban is **coagulation factor X in its activated form (FXa)**. FXa plays a central role in the blood coagulation cascade by catalyzing the conversion of prothrombin to thrombin—a key step leading to fibrin clot formation. By selectively and competitively inhibiting both free and clot-associated FXa with high specificity (>10,000-fold over other serine proteases), rivaroxaban effectively reduces thrombin generation and prevents pathological blood clot formation. This mechanism underlies its clinical use for preventing and treating conditions such as deep vein thrombosis, pulmonary embolism, stroke associated with non-valvular atrial fibrillation, and other thromboembolic disorders[1][2][4][8]. **Note:** The query lists "Rivaroxaban" as the target; however, rivaroxaban is actually the drug name—not the biological target. The correct canonical therapeutic target should be "Coagulation factor X (activated)" or "Factor Xa." Therefore, *is_incorrect* = true because "Rivaroxaban" refers to the inhibitor/drug rather than its molecular/protein target[1][2].

Other names

Factor XaActivated factor XFXaCoagulation factor XaFA10_HUMAN[5]

Direct inhibition of the active site of Factor Xa, blocking both free and clot-bound forms without requiring a cofactor such as antithrombin III[2][8]